These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1092 related articles for article (PubMed ID: 17707430)

  • 1. The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children.
    Franco I; Landau-Dyer L; Isom-Batz G; Collett T; Reda EF
    J Urol; 2007 Oct; 178(4 Pt 2):1775-9; discussion 1779-80. PubMed ID: 17707430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum A toxin urethral sphincter injection in children with nonneurogenic neurogenic bladder.
    Mokhless I; Gaafar S; Fouda K; Shafik M; Assem A
    J Urol; 2006 Oct; 176(4 Pt 2):1767-70; discussion 1770. PubMed ID: 16945643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.
    Smith CP; Nishiguchi J; O'Leary M; Yoshimura N; Chancellor MB
    Urology; 2005 Jan; 65(1):37-41. PubMed ID: 15667859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
    Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B
    J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents.
    Kuo HC
    Urology; 2004 May; 63(5):868-72. PubMed ID: 15134967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing concepts concerning the management of vesicoureteral reflux.
    Herndon CD; DeCambre M; McKenna PH
    J Urol; 2001 Oct; 166(4):1439-43. PubMed ID: 11547107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin type A in combination with standard urotherapy for children with dysfunctional voiding.
    Petronijevic V; Lazovic M; Vlajkovic M; Slavkovic A; Golubovic E; Miljkovic P
    J Urol; 2007 Dec; 178(6):2599-602; discussion 2602-3. PubMed ID: 17945299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics.
    Kuo HC
    Urology; 2005 Jul; 66(1):94-8. PubMed ID: 15992869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and durability of botulinum-A toxin for refractory dysfunctional voiding in children.
    Vricella GJ; Campigotto M; Coplen DE; Traxel EJ; Austin PF
    J Urol; 2014 May; 191(5 Suppl):1586-91. PubMed ID: 24679879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor.
    Hoebeke P; De Caestecker K; Vande Walle J; Dehoorne J; Raes A; Verleyen P; Van Laecke E
    J Urol; 2006 Jul; 176(1):328-30; discussion 330-1. PubMed ID: 16753434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysfunctional voiding in women.
    Carlson KV; Rome S; Nitti VW
    J Urol; 2001 Jan; 165(1):143-7; discussion 147-8. PubMed ID: 11125384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity.
    Schulte-Baukloh H; Knispel HH; Stolze T; Weiss C; Michael T; Miller K
    Urology; 2005 Oct; 66(4):865-70; discussion 870. PubMed ID: 16230156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it reasonable to treat refractory voiding dysfunction in children with botulinum-A toxin?
    Radojicic ZI; Perovic SV; Milic NM
    J Urol; 2006 Jul; 176(1):332-6; discussion 336. PubMed ID: 16753436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients.
    Mascarenhas F; Cocuzza M; Gomes CM; Leão N
    Neurourol Urodyn; 2008; 27(4):311-4. PubMed ID: 17914742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity.
    Karsenty G; Reitz A; Lindemann G; Boy S; Schurch B
    Urology; 2006 Dec; 68(6):1193-7. PubMed ID: 17141831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction.
    Schulte-Baukloh H; Weiss C; Stolze T; Stürzebecher B; Knispel HH
    Urology; 2005 Jul; 66(1):82-7. PubMed ID: 15992872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
    Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
    J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breaking the vicious circle: Onabotulinum toxin A in children with therapy-refractory dysfunctional voiding.
    't Hoen LA; van den Hoek J; Wolffenbuttel KP; van der Toorn F; Scheepe JR
    J Pediatr Urol; 2015 Jun; 11(3):119.e1-6. PubMed ID: 25794865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux.
    Karsenty G; Elzayat E; Delapparent T; St-Denis B; Lemieux MC; Corcos J
    J Urol; 2007 Mar; 177(3):1011-4. PubMed ID: 17296399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction.
    Kuo HC
    J Urol; 2003 Nov; 170(5):1908-12. PubMed ID: 14532805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.